Topics:
Gynecologic Cancers • Endometrial Cancer • Medical Oncology • ASCO Journal Club • Journal Club ft. NEJM publications • Immune Checkpoint Inhibitor
Would you recommend adjuvant chemo+IO +/- olaparib for patients with occult stage III disease identified after staging surgery with no measurable residual disease?
Answer from: at Academic Institution
Although most of those patients were not included in the trial, it is definitely a discussion I would have for patients with MMRd tumors and would recommend it to them.
I would for MMRd patients although they were not included in the trial if they had stage 3 endometrioid histology. More data on th...
Sign in or Register to read more
Answer from: at Community Practice
This is an important and relevant question. The strength of the GY-018 and RUBY trials lies in the consistency of the data, informing the benefit of adding ICI to chemotherapy and then as maintenance. This benefit was dramatic in the dMMR cohort (essentially identical HR of 0.30/0.28). In the dMMR p...
Answer from: at Community Practice
At this time I believe it is premature to change adjuvant chemo + /- RT to adjuvant chemo +/- IO. As mentioned, none of the phase III trials DUO-E, GY018, and RUBY included stage III disease without measurable disease. We don’t have any randomized trials in this setting to answer the ques...
Answer from: at Academic Institution
The recent results from GY018, RUBY, and DUO-E have changed the landscape in how we treat our advanced endometrial cancer patients. All three trials have shown improved progression free survival in patients receiving immunotherapy +/- olaparib in combination with and following standard-of-care chemo...